Loading
Four months of hormone therapy around radiotherapy improved survival in men with early prostate cancer, with the benefit confined to intermediate-risk disease, so short-course androgen deprivation became standard for that group.
Phase 3 trial of 1,979 men with T1b to T2b prostate cancer and PSA of 20 or less randomised to radiotherapy alone or with four months of androgen deprivation beginning two months before radiotherapy.
Ten-year overall survival was 62 versus 57 percent and prostate cancer mortality 4 versus 8 percent with androgen deprivation; the benefit was seen in intermediate-risk men (ten-year survival 61 versus 54 percent) and not in low-risk men.
Short-term androgen deprivation with radiotherapy is standard for unfavourable intermediate-risk prostate cancer; low-risk men do not need it.
Shares Localised prostate cancer, intermediate risk, New England Journal of Medicine.
Shares Localised prostate cancer, intermediate risk, New England Journal of Medicine.
Shares Localised prostate cancer, intermediate risk, New England Journal of Medicine.
Shares Localised prostate cancer, intermediate risk, New England Journal of Medicine.
Shares Localised prostate cancer, intermediate risk, New England Journal of Medicine.
Shares Localised prostate cancer, intermediate risk, New England Journal of Medicine.
Shares Localised prostate cancer, intermediate risk, New England Journal of Medicine.
Shares Localised prostate cancer, intermediate risk, New England Journal of Medicine.